Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT03117309. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase II trial of nivolumab in 120 treatment naïve patients with ccRCC.
Study identification
- NCT ID
- NCT03117309
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 164 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab 240 mg Drug
- Ipilimumab 1mg/kg Drug
- Nivolumab 3mg/kg Drug
- Nivolumab 360mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 24, 2017 (Actual)
- Primary completion
- Mar 25, 2022 (Actual)
- Completion
- Jan 23, 2025 (Actual)
- Last update posted
- Jul 10, 2025
2017 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Yale University, Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20057 | — |
| Winship Cancer Institute of Emory University | Atlanta | Georgia | 30322 | — |
| Northwestern University Feinberg Schooll Of Medicine | Chicago | Illinois | 60611 | — |
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | — |
| Beth Isreal Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Columbia University | New York | New York | 10032 | — |
| Cleveland Clinic | Cleveland | Ohio | 44915 | — |
| Univeristy of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03117309, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03117309 live on ClinicalTrials.gov.